Clin2
NCT07078357Worth exploringNot yet recruiting

Safety and immune response study of a strep vaccine

Rheumatic Heart DiseaseRheumatic Heart Disease in ChildrenVaccine Adverse ReactionRheumatic DiseasesVaccine AcceptanceVaccine

Part of Bones, joints & muscles, Heart & circulation, Infections, Skin clinical trials.

This trial tests a vaccine called StreptInCor to see if it's safe and helps the body build immunity against strep bacteria. It may help prevent serious complications like rheumatic fever and heart damage.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
60 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You must be a healthy adult between 18 and 45 years old.
  • You cannot have had any strep infection symptoms (like sore throat or fever) in the last 4 weeks.
  • No history of heart disease, rheumatic fever, chorea, or kidney disease in you or your close family.
  • No active infections like HIV or hepatitis, and no autoimmune diseases (like lupus or rheumatoid arthritis).
  • You must not be pregnant, breastfeeding, or planning a pregnancy if you are female.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07790302Not yet recruiting
Testing a vaccine to prevent rheumatic heart disease in children

This study is testing whether a vaccine can prevent rheumatic heart disease in children. It involves children aged 5 to 8 years who are healthy, live in certain areas, and have no history of heart problems. The study will check children's hearts with an ultrasound and follow them over time.

Kampala, Uganda
NCT07087912Recruiting· Phase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases

This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.

São Paulo, São Paulo
NCT07252804Recruiting· Phase 4
Testing the MenB vaccine safety and immune response in children with rheumatic disease

This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.

São Paulo, São Paulo
NCT07085702Recruiting· Phase 1
Testing a new Strep A vaccine in healthy young adults

This study tests a new vaccine designed to protect against Group A Strep bacteria. It will check how safe the vaccine is and how well it boosts your immune system. Healthy young adults between 18 and 25 years old may be eligible.

Botany, New South Wales
NCT07616934Recruiting· Phase 1
Safety and immune response study of VAX-A1 vaccine in healthy young adults

This study tests a new vaccine called VAX-A1 in healthy people aged 18–40 to see if it's safe and if it helps the body build protection against Group A Streptococcus (a bacteria that can cause serious infections). You'll receive two vaccine doses and have blood tests and heart monitoring over 6 months.

Adelaide, South Australia
NCT07712380Not yet recruiting· Phase 2
Vaccines and heart plaque study for adults 50+

This study tests if two new vaccines (one for shingles, one for RSV) affect heart artery plaque in people 50 and older who have some risk factors for heart disease. It aims to see if the vaccines are safe and if they slow plaque buildup.

Hear when a new Rheumatic Heart Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.